

# Davide Ciardiello

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8055258/publications.pdf>

Version: 2024-02-01

55  
papers

1,513  
citations

430874

18  
h-index

361022

35  
g-index

56  
all docs

56  
docs citations

56  
times ranked

2090  
citing authors

#	ARTICLE	IF	CITATIONS
1	Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective. <i>Seminars in Cancer Biology</i> , 2022, 86, 997-1007.	9.6	8
2	Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. <i>Clinical Colorectal Cancer</i> , 2022, 21, 141-148.	2.3	10
3	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 820.	4.1	15
4	Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day. <i>Biomedicines</i> , 2022, 10, 411.	3.2	11
5	Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 109.	8.6	7
6	Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. <i>Diagnostics</i> , 2022, 12, 685.	2.6	1
7	Immunotherapy in advanced anal cancer: Is the beginning of a new era?. <i>Cancer Treatment Reviews</i> , 2022, 105, 102373.	7.7	12
8	Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab. <i>International Journal of Cancer</i> , 2022, 151, 473-480.	5.1	24
9	Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210968.	3.2	8
10	Clinical management of metastatic colorectal cancer in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 372-401.	329.8	167
11	Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR. <i>Cancers</i> , 2022, 14, 3053.	3.7	7
12	Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 15.	8.6	13
13	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. <i>Clinical Cancer Research</i> , 2021, 27, 2515-2522.	7.0	39
14	Dual inhibition of TGF $\beta$ 2 and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. <i>Medical Oncology</i> , 2021, 38, 24.	2.5	7
15	Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New Results. <i>Journal of Personalized Medicine</i> , 2021, 11, 206.	2.5	2
16	Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 1941.	3.7	21
17	Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3578-3578.	1.6	6
18	Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities. <i>Vaccines</i> , 2021, 9, 623.	4.4	17

#	ARTICLE	IF	CITATIONS
19	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With <i>RAS</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1529.	7.1	80
20	How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4719.	3.7	7
21	Cutaneous Metastasis from Colorectal Cancer: Making Light on an Unusual and Misdiagnosed Event. <i>Life</i> , 2021, 11, 954.	2.4	3
22	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. <i>Clinical Colorectal Cancer</i> , 2021, 20, 227-235.	2.3	10
23	Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1166.	4.1	10
24	<i>BRAF</i> , <i>MEK</i> and <i>EGFR</i> inhibition as treatment strategies in <i>BRAF</i> V600E metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199297.	3.2	38
25	Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. <i>Cancers</i> , 2021, 13, 5715.	3.7	6
26	Baseline IFN- $\gamma$ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. <i>Scientific Reports</i> , 2020, 10, 17626.	3.3	20
27	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in <i>RAS</i> wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 138, 1-10.	2.8	23
28	Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093608.	3.2	37
29	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 653-664.	3.1	7
30	Optimal treatment strategy for metastatic melanoma patients harboring <i>BRAF</i> -V600 mutations. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092521.	3.2	31
31	Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania "Luigi Vanvitelli". <i>ESMO Open</i> , 2020, 5, e000675.	4.5	11
32	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. <i>Cancer Treatment Reviews</i> , 2020, 86, 102023.	7.7	34
33	Light Alcohol Drinking and the Risk of Cancer Development: A Controversial Relationship. <i>Reviews on Recent Clinical Trials</i> , 2020, 15, 164-177.	0.8	4
34	Critical review on the use and abuse of alcohol. When the dose makes the difference. <i>Minerva Medica</i> , 2020, 111, 344-353.	0.9	6
35	Patient and tumor characteristics as determinants of overall survival (OS) in <i>BRAF</i> V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 4112-4112.	1.6	6
36	Clinical Practice Use of Liquid Biopsy to Identify <i>RAS</i> / <i>BRAF</i> Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. <i>Cancers</i> , 2019, 11, 1504.	3.7	36

#	ARTICLE	IF	CITATIONS
37	Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells. <i>Cancers</i> , 2019, 11, 1430.	3.7	15
38	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 41.	8.6	57
39	Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 236.	8.6	17
40	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. <i>Cancer Treatment Reviews</i> , 2019, 76, 22-32.	7.7	224
41	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 845-855.	4.1	58
42	Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature. <i>ESMO Open</i> , 2019, 4, e000551.	4.5	15
43	A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant. <i>Medicine (United States)</i> , 2019, 98, e15759.	1.0	6
44	Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS731-TPS731.	1.6	7
45	Abstract 2627: Inhibition of TGF $\beta$ 2 in colorectal cancer cells is associated with a compensatory activation of AXL and p38 MAPK signaling pathways. <i>Cancer Research</i> , 2019, 79, 2627-2627.	0.9	2
46	Abstract 295: Synergism between oxaliplatin or irinotecan with the PARP inhibitor niraparib in a preclinical model of KRAS/BRAF mutated colorectal cancer is associated with MSI status. , 2019, , .		0
47	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , 2018, 3, e000299.	4.5	29
48	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , 2017, 23, 4675.	3.3	91
49	Implication of the Hedgehog pathway in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 4330.	3.3	54
50	Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. <i>Oncotarget</i> , 2017, 8, 67592-67604.	1.8	15
51	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. <i>Clinical Cancer Research</i> , 2015, 21, 4153-4164.	7.0	21
52	AXL is an oncotarget in human colorectal cancer. <i>Oncotarget</i> , 2015, 6, 23281-23296.	1.8	55
53	Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 279-287.	0.5	0
54	Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. <i>Clinical Cancer Research</i> , 2014, 20, 3775-3786.	7.0	89

#	ARTICLE	IF	CITATIONS
55	CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients. Frontiers in Oncology, 0, 12, .	2.8	14